Leerink Partners

Latest articles

4d
Market Watch
UnitedHealth earnings: Insulated from Obamacare, Amazon and still going strongwith “owned physician practices, physician networks, integrated medical and Rx
Market Watch / Posted 4 days ago
with “owned physician practices, physician networks, integrated medical and Rx benefits and local market presence,” said Leerink Partners analyst Ana Gupte. “AMZN could be a preferred partner that can boost market share but is less of a... Read more
4d
New York Post
Wonder drug regulates hormones in both men and womenalready does it. But that drug has to be injected, has safety issues and is not
New York Post / Posted 4 days ago
already does it. But that drug has to be injected, has safety issues and is not supposed to be used in the long term, said Leerink Partners analyst Jason Gerberry. The uterine fibroids and endometriosis markets are “both large, but there are no... Read more
6d
Market Watch
This drug may have a shot at both women’s health disorders and prostate canceralready does it. But that drug has to be injected, has safety issues and is not
Market Watch / Posted 6 days ago
already does it. But that drug has to be injected, has safety issues and is not supposed to be used in the long term, said Leerink Partners analyst Jason Gerberry. The uterine fibroids and endometriosis markets are “both large, but there are no... Read more
8d
Market Watch
Is Amazon getting into the pharmacy business? This is what you need to knowbusiness, Gupte said. CVS, though, might be able to leverage its pharmacy-bene
Market Watch / Posted 8 days ago
business, Gupte said. CVS, though, might be able to leverage its pharmacy-benefit manager unit to reduce its risk, said Leerink Partners analyst David Larsen. Anticipated competition from Amazon could also prompt pharmacies to diversify their... Read more
3 related articles
11d
Business Wire
ImmunoGen Announces Pricing of Public Offering of Common Stockcommercialization preparation, acquisitions of new technologies, capital expend
Business Wire / Posted 11 days ago
commercialization preparation, acquisitions of new technologies, capital expenditures and working capital. Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity is... Read more
11d
FOX Business
Why EXACT Sciences Corporation Jumped 13.2% in Septemberaccording to data from S&P Global Market Intelligence. While it was a quiet mon
FOX Business / Posted 11 days ago
according to data from S&P Global Market Intelligence. While it was a quiet month on the news front, an analyst at Leerink Partners released a bullish note to the investment community that helped to explain the rally.So what Shareholders... Read more
11d
FOX Business
Why EXACT Sciences Corporation Jumped 13.2% in Septemberaccording to data from S&P Global Market Intelligence. While it was a quiet mon
FOX Business / Posted 11 days ago
according to data from S&P Global Market Intelligence. While it was a quiet month on the news front, an analyst at Leerink Partners released a bullish note to the investment community that helped to explain the rally.So what Shareholders... Read more
12d
Business Wire
Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Sharesand other estimated offering expenses, were approximately $215.8 million. J.P.
Business Wire / Posted 12 days ago
and other estimated offering expenses, were approximately $215.8 million. J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC acted as joint book-running managers for the offering. The shares were offered by Acceleron pursuant to... Read more
2 related articles
13d
Market Watch
Immunogen shares fall after secondary share offering announcedplans to offer 13 million shares, and provide underwriters with up to 2 million
Market Watch / Posted 13 days ago
plans to offer 13 million shares, and provide underwriters with up to 2 million shares to cover overallotments. Jefferies, Leerink Partners and RBC Capital Markets are listed as underwriters. Immunogen intends to use proceeds to finance research... Read more
15d
FOX Business
AbbVie Stock Upgradedthe rest of the S&P 500. But now here's the best news of all: According to the
FOX Business / Posted 15 days ago
the rest of the S&P 500. But now here's the best news of all: According to the analysts at Boston-based investment banker Leerink Partners, AbbVie stock is poised to keep on outperforming the S&P 500 for some time to come. Here are three things... Read more
15d
FOX Business
AbbVie Stock Upgradedthe rest of the S&P 500. But now here's the best news of all: According to the
FOX Business / Posted 15 days ago
the rest of the S&P 500. But now here's the best news of all: According to the analysts at Boston-based investment banker Leerink Partners, AbbVie stock is poised to keep on outperforming the S&P 500 for some time to come. Here are three things... Read more
18d
Market Watch
Sarepta Therapeutics shares dive on safety issues in FDA databaseprogressive fatal disease like DMD and are not necessarily due to any mechanist
Market Watch / Posted 18 days ago
progressive fatal disease like DMD and are not necessarily due to any mechanistic or safety flaws of the drug itself," said Leerink Partners analyst Joseph Schwartz. Company management told Leerink that the reported deaths happened in patients late... Read more
19d
Business Wire
Nightstar Announces Pricing of Initial Public Offeringcommissions. The offering is expected to close on October 2, 2017, subject to c
Business Wire / Posted 19 days ago
commissions. The offering is expected to close on October 2, 2017, subject to customary closing conditions. Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush... Read more
3 related articles
25d
Business Wire
Sage Therapeutics to Participate in Leerink Investor Conferenceto treat life-altering central nervous system (CNS) disorders, today announced
Business Wire / Posted 25 days ago
to treat life-altering central nervous system (CNS) disorders, today announced that the Company will participate in the Leerink Partners Rare Disease Roundtable on Wednesday, September 27, 2017, with a presentation at 2:00 p.m. ET in New York,... Read more
25d
FOX Business
Why Exelixis, Inc. Slumped TodayWhat happened Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an a
FOX Business / Posted 25 days ago
What happened Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing to the downward direction of the share... Read more
25d
FOX Business
Why Exelixis, Inc. Slumped TodayWhat happened Continue Reading Below Exelixis(NASDAQ: EXEL) is down 12.3% at
FOX Business / Posted 25 days ago
What happened Continue Reading Below Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing to the downward... Read more
25d
Market Watch
Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trialbiweekly dose schedule was viewed as preferable to Ascendis Pharma’s ASND, +43.
Market Watch / Posted 25 days ago
biweekly dose schedule was viewed as preferable to Ascendis Pharma’s ASND, +43.33% weekly dose schedule, according to Leerink Partners analyst Joseph Schwartz, and the Versartis product had been expected to launch about a year earlier than... Read more
25d
Business Wire
Juno Therapeutics Prices $250 Million Follow-on Offeringshares in full). Morgan Stanley and J.P. Morgan are acting as joint book-runni
Business Wire / Posted 25 days ago
shares in full). Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Barclays and Leerink Partners are acting as co-lead managers and Wells Fargo Securities, Raymond James and Wedbush PacGrow are acting as... Read more
26d
Business Wire
Acceleron Announces Pricing of Public Offering of Common Stocka 30-day option to purchase up to an additional 810,810 shares of common stock.
Business Wire / Posted 26 days ago
a 30-day option to purchase up to an additional 810,810 shares of common stock. J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering. The offering is expected to close on or... Read more
26d
Stamford Advocate
Amazon is making noise in pharma these days — here's what it could all meanis tip-toeing around the pharmacy space sent Wall Street scrambling to understa
Stamford Advocate / Posted 26 days ago
is tip-toeing around the pharmacy space sent Wall Street scrambling to understand CEO Jeff Bezos' next move. Analysts at Leerink Partners wrote that Amazon may be in discussions with mid-sized pharmacy benefit managers "in an effort to get into... Read more
26d
Connecticut Post
Amazon is making noise in pharma these days — here's what it could all meanis tip-toeing around the pharmacy space sent Wall Street scrambling to understa
Connecticut Post / Posted 26 days ago
is tip-toeing around the pharmacy space sent Wall Street scrambling to understand CEO Jeff Bezos' next move. Analysts at Leerink Partners wrote that Amazon may be in discussions with mid-sized pharmacy benefit managers "in an effort to get into... Read more
27d
Crain's Chicago Business
Amazon eyes mail-order drug businessfor $13.4 billion, Amazon is in talks with pharmacy benefit managers, according
Crain's Chicago Business / Posted 27 days ago
for $13.4 billion, Amazon is in talks with pharmacy benefit managers, according to a note published by the investment bank Leerink Partners. The move indicates the retail behemoth may be preparing to enter the mail-order drug business. Pharmacy... Read more
27d
Market Watch
Alnylam shares surge 40% on drug results that may herald a new type of medicinehalted a hemophilia drug’s development earlier this month and was forced to dis
Market Watch / Posted 27 days ago
halted a hemophilia drug’s development earlier this month and was forced to discontinue another drug last fall, said Leerink Partners analyst Paul Matteis. The results also appear to be a best-case scenario for the company, he said, noting... Read more
28d
Business Wire
Acceleron Announces Proposed Public Offering of Common StockAll of the shares in the proposed offering are to be sold by Acceleron. J.P. M
Business Wire / Posted 28 days ago
All of the shares in the proposed offering are to be sold by Acceleron. J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering. Acceleron intends to use the net proceeds... Read more
29d
Market Watch
Nabriva Therapeutics’ latest good news soothes concerns about chief medical officer’s departureconcerns surrounding the resignation just ahead of the data,” especially given
Market Watch / Posted 29 days ago
concerns surrounding the resignation just ahead of the data,” especially given how detailed Monday’s release was, said Leerink Partners analyst Paul Matteis. The latest clinical trial results found that the drug is about as effective as the... Read more

In this news